Treatment of nonfunctioning neuroendocrine tumors with somatostatin analogs has been controversial, given the low antitumor effects of these drugs. The PROMID study group now reports that octreotide LAR (long-acting release) has a substantial antitumor effect, with longer progression-free survival compared with placebo in patients with well-differentiated neuroendocrine tumors and low tumor burden.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yao, J. C. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063–3072 (2008).
Feldman, J. M. Carcinoid tumors and syndrome. Semin. Oncol. 14, 237–246 (1987).
Oberg, K. et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann. Oncol. 15, 966–973 (2004).
Rinke, A. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27, 4656–4663 (2009).
Plöckinger, U. & Wiedenmann, B. Neuroendocrine tumors. Biotherapy. Best Pract. Res. Clin. Endocrinol. Metab. 21, 145–162 (2007).
Reubi, J. C., Waser, B., Schaer, J. C. & Laissue, J. A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 28, 836–846 (2001).
Susini, C. & Buscail, L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 17, 1733–1742 (2006).
Imtiaz, K. E., Monteith, P. & Khaleeli, A. Complete histological regression of metastatic carcinoid tumor after treatment with octreotide. Clin. Endocrinol. 53, 755–758 (2000).
Granberg, D., Jacobsson, H., Oberg, K., Gustavsson, J. & Lehtihet, M. Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report. Digestion 77, 92–95 (2008).
Rindi, G. et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 451, 757–762 (2007).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares associations with the following companies: Ipsen Pharma S.A.S (speakers bureau), Novartis AG (speakers bureau).
Rights and permissions
About this article
Cite this article
Oberg, K. Antitumor effects of octreotide LAR, a somatostatin analog. Nat Rev Endocrinol 6, 188–189 (2010). https://doi.org/10.1038/nrendo.2010.3
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2010.3
This article is cited by
-
Wilms tumor-suppressing peptide inhibits proliferation and induces apoptosis of Wilms tumor cells in vitro and in vivo
Journal of Cancer Research and Clinical Oncology (2019)
-
A case of pancreatic neuroendocrine tumors
International Cancer Conference Journal (2016)
-
Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours
European Journal of Nuclear Medicine and Molecular Imaging (2014)
-
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study
Journal of Translational Medicine (2013)
-
Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin
Investigational New Drugs (2013)
